Compare AstraZeneca plc (AZN) vs Corning Incorporated (GLW) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Corning (GLW) trades at $183.36, down 3.92% amid a broader AI infrastructure stock selloff. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $0.70 versus $0.692 expected, marking the fourth consecutive earnings beat. Revenue growth accelerated to $15.63 billion in 2025 with net income margin improving to 10.21%. Technical indicators show bearish momentum with the price testing support at $181, while RSI at 46.51 suggests neutral momentum conditions.

GLW presents a compelling long-term opportunity with 54% analyst buy ratings and a $210.10 consensus price target representing 15% upside. Key risks include China exposure, consumer electronics cyclicality, and competitive pressures in optical communications. The company's AI partnerships with NVIDIA and Amazon position it well for sustained growth in fiber and connectivity markets despite recent volatility.